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Dr. Jyotishka Datta, Virginia Tech, Statistics.
"The inspiration of the 
camel image is that it 
represents the 
dedication of the world 
to bring vaccines to 
everyone."
- Halloran et al. (2009), 
Design & Analysis of 
Vaccine Studies
On May 10, 2021
November 20, 2020, New York Times, Carl Zimmer
Efficacy • Vaccine efficacy (and vaccine effectiveness), VE, are generally estimated as one minus some measure of 
relative risk, RR, in the vaccinated group compared to 
the unvaccinated group:
VE = 1 - RR
• The groups being compared could be composed of 
individuals or of populations or communities.
Pfizer
• Pfizer recruited 43,661 
volunteers and waited 
for 170 people to come 
down with symptoms of 
Covid-19 and get a 
positive test.
• Out of these 170, 162 
were from the 'placebo’ 
group and just 
eight were from the 
‘vaccine’ group.









Placebo 21,830 162 162/21830= 
0.74%
2.5 million




• Recall, VE = 1 – RR = 1 - (risk for vaccine 
group)/(risk for placebo)
• Placebo group's infection risk: 0.74%
• Vaccine group's infection risk: 0.04%
• VE = 1 – 0.04/0.74 = (0.74 - 0.04)/0.74 = 0.95
• This captures the difference in impact by scaling 
the percentage point difference in risks by the 
original infection risk.
• What factors influence efficacy? How do we 
control for age, gender, ethnicity, co-morbidities 
etc.?
Piero Olliaro, “What Does 95% COVID-19 Vaccine Efficacy Really Mean?” 
Quote from 
the letter
• "The mRNA-based Pfizer and Moderna vaccines 
were shown to have 94–95% efficacy in 
preventing symptomatic COVID-19, calculated as 
100 × (1 minus the attack rate with vaccine divided 
by the attack rate with placebo)."
• "It means that in a population such as the one 
enrolled in the trials, with a cumulated COVID-19 
attack rate over a period of 3 months of about 1% 
without a vaccine, we would expect roughly 0·05% 
of vaccinated people would get diseased."
• "It does not mean that 95% of people are 
protected from disease with the vaccine—a general 
misconception of vaccine protection also found in a 
Lancet Infectious Diseases Editorial."












This Photo by Unknown author is licensed under CC BY-SA-NC.
History of 
vaccines
• The word vaccine was derived from Latin 
word 'vacca' for cow*, when English 
physician Edward Jenner introduced 
cowpox-based vaccine against smallpox 
in 1796.
• Apparently, that story was probably not 
correct. As an NEJM article showed in 
2017 (by analyzing historical containers), 
the vaccine used to prevent small-pox 
was horse-pox, and maybe ... we should 
have called it 'equusine'.
Historical 
Perspectives
"The fundamental logic 
behind today’s vaccine 
trials was worked out by 
statisticians over a century 
ago."
Through the centuries
• After nearly a 100-years of hiatus, at the end of the 19th century, inoculations against 
cholera, typhoid, plague (caused by bacteria) and rabies (caused by a virus) were 
developed
• By the early 20th century, legendary statisticians Karl Pearson, Major 
Greenwood, and Udny Yule were deeply engaged in discussions 
of assessing these vaccines in the field.
• 1920's: Pertussis, diptheria, tetanus, and bacille Calmette-Gu´erin against 
tuberculosis
• 1930's: yellow fever, influenza, and rickettsia vaccines




• Famous opening line:
• “Hardly any subjects within 
the range of preventive medic
ine is of more immediate 
importance than the methods 
of prophylaxis which ought to 
be adopted with respect to 
typhoid fever and cholera”
Why two 
tables?
• Whether to “class as 
inoculated those who were so 
at the date of the last return
made or only those 
actually inoculated at the 




• In the former case, there 
may be an exaggeration of 
the “number of men who 
were inoculated during the 
whole exposure to infection,”
• In the latter case, one 
would underestimate it 
“because many inoculations 
were done shortly after 
arrival”
• How to adjust for this effect?
• Pre-date formal 'randomized 
studies'
Poliomyelitis vaccine
• In 1954, an enormous field study - total of 
1,829,916 children participated in the 
nationwide study.
• Observed control study.
• "to administer vaccine to children in the 
second grade of school; the 
corresponding first and third graders 
would not be inoculated, but would be 
kept under observation for the 
occurrence of poliomyelitis in comparison 
with the inoculated second graders”
• not a blinded study + effect of age might 
lead to bias !!
Poliomyelitis vaccine
• The plan was changed in mid-stream. In the second 
plan, called the Placebo Control Study, “children of 
the first, second, and third grades would be 
combined. One half would receive vaccine; the other 
matching half, serving as strict controls, would 
receive a solution of similar appearance (placebo)”
• Despite flaws, this vaccine had 72% efficacy.
• The Salk (injected) and Sabin (oral) polio 
vaccines have been 'transformative' - three polio virus 







• Double-blinded randomized controlled trial (RCT)
• Group of participants placed either in a control 
group or experimental, completely at random, 
people going in are not aware of which group 
they're in, neither the researchers.
• The idea is that the experimental & control groups 
would be similar in terms of potential factors, 
such as, age, gender, ethnicity etc.
• Keep in mind: There could be issues of ethics 
("necessary to know if the vaccine was better than 
what was available at the time")




"Efficacy was consistent across age, gender, race and 
ethnicity demographics; observed efficacy in adults 
over 65 years of age was over 94%"
"The Phase 3 clinical trial of BNT162b2 began on July 
27 and has enrolled 43,661 participants to date, 
41,135 of whom have received a second dose of the 
vaccine candidate as of November 13, 2020".
"Approximately 42% of global participants and 30% 
of U.S. participants have racially and ethnically 
diverse backgrounds, and 41% of global and 45% of 
U.S. participants are 56-85 years of age."

Efficacy depends on a lot of things!
• Where? J&J conducted trials in US, Latin America, 
South Africa.
• Overall efficacy lower than US-specific efficacy.
• In South Africa, trials took place after a new 
variants B.1.351 emerged, affecting the efficacy.
• But it didn't make it useless (SA efficacy ~ 64%)
• Also, when do we look at outcomes? J&J has 85% 
efficacy against severe cases.
Direct & Indirect effects
• Safe & effective vaccine strategy 
offers both
(1) direct protection (high-risk) and
(2) indirect (reduce transmission for 
those in contact with high-risk).
Marc Lipsitch and Natalie E. Dean, “Understanding COVID-19 Vaccine 
Efficacy”, Science. 
Strategy
• Elderly & people with comorbidities are at 
greatest risk - age structured mathematical 
models.
• Need to know well the vaccine works in 
which groups.
• Phase 3 trials provide insights about 
individual level efficacy & safety.
• However, assessing subgroup-specific 
efficacy is often challenging, and needs 
more work.
• For example, blinded follow-up studies can 
provide evidence on long-term safety, 
efficacy & age-specific effects.
Uncertainty
Uncertainty • The efficacy numbers you see (e.g., 95%) are 
point estimates.
• For the general 
population, there will 
be 'uncertainty' -
reflects the difference 
between the 
subjects under trial and 
the large population.
• 95% confidence 
intervals.
Uncertainty
• One way to think 
about 95% CI's is that if 
you conduct 100 such 
similar studies, 95 
of them would contain 
the efficacy value.
• FDA's threshold: 
efficacy no less than 
50% & lower limit of 
CI cannot be lower than 
30%




• The last thing to note 
about CI's is that if there's 
a large overlap between 
two CI's, then their 
difference is not 
statistically significant.
• In case of vaccines, it 
means that the point 
estimates of the efficacy 
values might be different, 
but if the CI's overlap, their 
efficacies are not really 
distinguishable.
• There are other factors as 
well.
How do vaccines 
compare?
• It is very difficult to compare vaccines.
• Vaccines were tested on different groups of 
people, during different stages of pandemic.
• They were also measured in different ways –
e.g., J&J 28 days after a single dose, while 
Moderna 14 days after a second dose.
• All these vaccines have a high efficacy against 
hospitalization & death.








A clinical trial is not the final destination, but just a 
start.
Researchers follow the effects of vaccine on the 
large popoulation for a long time.
Then, the quantity to look at is called 
"effectiveness" - the relative reduction of risk in 'real 
world', millions or billions of people.
Early studies show that the vaccines are also quite 
effective.
Final remark
"A tale of personal 
perseverance" 
• Katalin Karikó was dismissed, ignored, 
unable to get grants and 
demoted. Had a cancer scare & 
her husband was stuck in Hungary 
sorting out visa issues.
• For three decades, she refused to 
quit.
• Ask yourselves, why did it have to be 
this way, and how many Katalin 
Karikos have quit?
Damian Garde, “The Story of MRNA: How a Once-Dismissed Idea 
Became a Leading Technology in the COVID Vaccine Race” 
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Questions
The Role of Open Access in COVID-19 Vaccine Research












What is Open Access?
• OPEN = IMPACT
• Open Access Publishing
• Open access (OA) refers to freely available, digital, online information. Open access 
scholarly literature is free of charge and often carries less restrictive copyright and 
licensing barriers than traditionally published works, for both the users and the 
authors. 
• While OA is a newer form of scholarly publishing, many OA journals comply with 
well-established peer-review processes and maintain high publishing standards.
• Digital Repositories like ScholarWorks@UARK
• Funding agencies are getting serious about compliance, and that means publicly 
funded research must be made available OA
Why Open 
Access?
Higher visibility for University of Arkansas 
authored works, with higher citation rates 
and greater impact in the field and beyond.
Publishing with established journals and 
presses using trusted peer review 
processes.
Opportunities to establish a strong early 
career publication record for tenure track 
faculty and student authors.
Helps those authors in disciplines who do 








• Public outcry from the 
scientific and research 
community
• Taxpayer funded research 
should be freely available 
• Data sharing and open 
peer review
• Full access to all research 
and publication
Controversy
• Quantity versus quality
• Other models for peer 
review
• The Lancet retraction 





• Scholarly Publication in 
Historical Context
• Societal Impact 
Cultural Shifts
• Is this a permanent 
change?
• Should it be?





• When will the program begin? July 1, 2021
• Is this a one time ask? Yes, this is a pilot program, and we will 
be assessing it for continuing.  
• Is there a plan for dedicated funding? Most research-intensive 
universities have had open access grant programs for a long 
time. These programs are typically centered within academic 
libraries and are funded every year by a combination of funding 
from partners across campus.
• Will there be limits on the number of asks, the total amount of 
requests, the frequency of asks, etc.? We will limit the 
requests per author to one per year to make sure the funding 
covers as many authors as possible.
• Open to students?  Yes, open to all institutional authors. 
• Are there caps on the grant amount? Open access grant funds 
at large universities typically cover between $1500 to $3000 per 
book or journal article funding request. We will cover up to $2000.
• How will the funding be managed?  As with other research 
institutions, the Libraries will administer the open access funds 
and the program will have clearly defined rules as to who is 
eligible, what publications are covered, and guidelines for 
applying.  These will be posted on the Office of Scholarly 
Communications page.  
Questions? 
